Browsing by Author "Roux, P"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Open Access
    BCG vaccination in South African HIV-exposed infants - risks and benefits
    (2009) Hesseling, A C; Caldwell, J; Cotton, M F; Eley, B S; Jaspan, H B; Jennings, K; Marais, B J; Nuttall, J; Rabie, H; Roux, P; Schaaf, H S
    Until 2007, the World Health Organization (WHO) recommended that bacille Calmette-Guérin (BCG) vaccination should be contraindicated in infants with symptomatic HIV disease in countries with a high burden of tuberculosis. This recommendation was based on the perceived low risk of serious adverse events in HIV-infected infants. The WHO revised its recommendations regarding BCG vaccination in HIV-infected infants in 2007, making HIV infection a full contraindication to BCG vaccination. BCG induces protective efficacy against tuberculous meningitis of 73% (67 - 79%) and against miliary disease of 77% (58 - 87%) in HIV-uninfected children. The efficacy against childhood pulmonary disease is variable;3 there is no evidence that BCG induces a protective effect against tuberculosis in HIV-infected infants and children. BCG is a safe vaccine in immunocompetent infants, and severe vaccine adverse events in HIV-uninfected infants occur only with rare primary immune deficiencies in approximately 1 per million vaccinees.
  • Thumbnail Image
    Item
    Open Access
    Refined identification of neutralization-resistant CRF02_AG viruses and their sensitivity to anti-MPER neutralizing antibodies
    (BioMed Central Ltd, 2012) Jacob, RA; Abrahams, F; Tongo, M; Schomaker, M; Roux, P; Ngole, E; Burgers, WA; Dorfman, JR
    The first antibody-inducing HIV-1 vaccines are unlikely to protect against all HIV-1 isolates. There is thus a danger that a vaccine will select for HIV-1 viruses that are highly resistant to antibody-mediated neutralization. We sought to identify and characterize such viruses.